AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal 
Samsung Chairman Lee Jae-yong Expected to Meet Nvidia CEO Jensen Huang on AI and Chip Partnership 
SK Hynix’s $28 Billion U.S. Share Sale Draws Massive Demand Amid AI Chip Boom 
SpaceX Stock Draws Bullish Wall Street Coverage Ahead of Nasdaq-100 Inclusion 
Telenor to Buy Controlling Stake in Bahnhof in $630 Million Broadband Deal 
Wolfspeed Sues Navitas Over GaN and SiC Patent Infringement 
Zhipu AI Stock Jumps on Report of Custom AI Chip Development Plans 
Fast Retailing Raises Full-Year Forecast After Uniqlo Owner Beats Q3 Profit Estimates 
Levi Strauss Raises 2026 Outlook After Q2 Earnings Beat, Shares Drop Despite Strong Results 
BHP Faces Port Hedland Strike Threat as Iron Ore Export Risks Grow 
Sino Biopharm Stock Rises After AstraZeneca Licensing Deal, GSK Partnership Expansion 
Apple Tests China's CXMT Memory Chips as DRAM Maker Gains Global Market Share 
Lockheed Martin, Rheinmetall Plan First ATACMS Missile Production in Germany 
Bain Capital Exits Kioxia After AI-Fueled Valuation Surge 
Oppenheimer Sees CNH Industrial as Top 2026 Agriculture Stock Pick on Dealer Consolidation Strategy 
Oil and LNG Tankers Turn Back as Strait of Hormuz Security Risks Escalate 
RADNOR, Pa., May 06, 2018 -- Kaskela Law LLC announces that a shareholder class action lawsuit has been filed against Molina Healthcare, Inc. (NYSE:MOH) (“Molina” or the “Company”) on behalf of purchasers of the Company’s securities between October 31, 2014 and August 2, 2017, inclusive (the “Class Period”).
Molina investors are encouraged to visit www.kaskelalaw.com/case/molina to receive additional information about this action and submit their information online. Investors may also contact attorney D. Seamus Kaskela at (888) 715 – 1740, or via email at [email protected], to discuss their legal rights and options with respect to this action.
The shareholder class action complaint alleges that Molina and certain of its executive officers misled investors about the scalability of the Company’s existing administrative infrastructure, and falsely claimed that the Company’s administrative infrastructure could support rapid growth into existing Medicaid markets and new Patient Protection and Affordable Care Act health insurance marketplaces in a cost-effective manner.
As detailed in the complaint, the truth about Molina’s failed growth strategy and inadequate administrative infrastructure was revealed through a series of partial disclosures, including the Company’s announcement of a major restructuring plan, and the reporting of disappointing financial results and significant restructuring costs and impairment losses. The complaint further alleges that, as a result of the foregoing, investors purchased Molina’s securities at artificially inflated prices during the Class Period and sustained significant investment losses when the truth was revealed.
Investors who purchased Molina securities during the Class Period may, no later than June 29, 2018, seek to be appointed as a lead plaintiff representative of the class through Kaskela Law or other counsel, or may choose to do nothing and remain an absent class member. In order to be appointed as a lead plaintiff a class member meet certain legal requirements.
Kaskela Law LLC exclusively prosecutes shareholder actions in state and federal courts throughout the country on behalf of investors. For additional information about Kaskela Law LLC please visit www.kaskelalaw.com.
CONTACT:
KASKELA LAW LLC
D. Seamus Kaskela, Esq.
201 King of Prussia Road
Suite 650
Radnor, PA 19087
(888) 715 – 1740
[email protected]
www.kaskelalaw.com
